Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04597151

Diet Education Program for Stage I-IV Colorectal Cancer Survivors

Stage IV Colorectal Cancer AJCC v8 Clinical Trial

Official title:
Diet Education Among Colorectal Cancer Survivors in the Safety Net Setting: A Pilot Feasibility Study

Clinical Trial Summary

This pilot trial evaluates the feasibility of a group diet education program for stage I-IV colorectal cancer survivors. Providing a nutrition education program for colon and rectal cancer survivors may help them have better access to the tools necessary to make healthy food decisions that can impact their cancer outcomes.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To describe the feasibility and acceptability of a group diet education intervention for colorectal cancer (CRC) survivors at Zuckerberg San Francisco General Hospital (ZSFGH). SECONDARY OBJECTIVE: I. To describe perceived barriers to healthy diet among CRC survivors at ZSFGH. EXPLORATORY OBJECTIVES: I. To evaluate for differences in feasibility and acceptability of a group diet education program, based on sociodemographic factors such as education, food insecurity, employment, and race. II. To explore changes in health-related behaviors pre and post intervention using a validated lifestyle score. OUTLINE: Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5). After completion of study, patients are followed up at 12 weeks. ;

Study Design

Related Conditions & MeSH terms

  • Colorectal Neoplasms
  • Stage I Colorectal Cancer AJCC v8
  • Stage II Colorectal Cancer AJCC v8
  • Stage IIA Colorectal Cancer AJCC v8
  • Stage IIB Colorectal Cancer AJCC v8
  • Stage IIC Colorectal Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage IIIA Colorectal Cancer AJCC v8
  • Stage IIIB Colorectal Cancer AJCC v8
  • Stage IIIC Colorectal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IVA Colorectal Cancer AJCC v8
  • Stage IVB Colorectal Cancer AJCC v8
  • Stage IVC Colorectal Cancer AJCC v8
Clinical Trial Details
NCT number NCT04597151
Study type Interventional
Source University of California, San Francisco
Contact
Status Completed
Phase N/A
Start date October 12, 2020
Completion date August 31, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05691491 - Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Phase 1/Phase 2
Terminated NCT04832763 - Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer N/A
Active, not recruiting NCT04164069 - Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Phase 1
Active, not recruiting NCT03981614 - Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Phase 2
Recruiting NCT05863195 - Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Phase 3
Active, not recruiting NCT03983993 - Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer Phase 2
Not yet recruiting NCT05518032 - Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) Phase 2
Recruiting NCT05803382 - Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers Phase 1
Not yet recruiting NCT05356897 - Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Phase 2
Recruiting NCT04314401 - National Cancer Institute "Cancer Moonshot Biobank"
Suspended NCT04111172 - A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Phase 2
Recruiting NCT05627635 - FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Phase 1/Phase 2
Active, not recruiting NCT04362839 - Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Phase 1
Recruiting NCT05672316 - Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy Phase 1/Phase 2
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Active, not recruiting NCT04117945 - Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT02983578 - Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Phase 2
Recruiting NCT04693377 - Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial N/A
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2
Completed NCT00862680 - 4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis